Inovio's COVID-19 vaccine is protective against variants of concern

By The Science Advisory Board staff writers

April 15, 2021 -- Inovio has announced promising results from a study focusing on the human immune responses induced by its DNA vaccine candidate for COVID-19, INO-4800.

Results showed that INO-4800 induced a robust T-cell response against all spike protein variants tested, which may be a key in providing protection against SARS-CoV-2 variants. In addition, the vaccine provides similar levels of neutralizing activity against both the U.K. and Brazilian variants of SARS-CoV-2 as those against the original strain.

More than 3,000 patients are receiving Inovio's investigational DNA medicines in more than 7,000 applications across a range of clinical trials. This latest study has been submitted for peer review and can be viewed on bioRxiv.

Clinical pipeline promises effective 2nd-generation COVID-19 vaccines
Despite the small number of COVID-19 vaccines that have been granted emergency use authorizations by the U.S. Food and Drug Administration to date, many...
Inovio to develop COVID-19 DNA-encoded monoclonal antibodies
Inovio, along with a team of scientists from the Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University, has received a...
Inovio expands COVID-19 vaccine manufacturing with Kaneka
Inovio has brought Belgium-based Kaneka Eurogentec on board a global consortium of companies that will be manufacturing its DNA COVID-19 vaccine INO-4800,...
Inovio begins late phase clinical trials for COVID-19 vaccine
Inovio has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with the phase II segment of its phase II/III clinical trial...
Thermo Fisher to manufacture Inovio's COVID-19 vaccine
Thermo Fisher Scientific has signed a letter of intent to manufacture Inovio's DNA COVID-19 vaccine candidate, INO-4800.

Copyright © 2021 scienceboard.net


Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter